The Latest Breaking News from Roche

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

Here's a roundup of top developments in the biotech space over the last 24 hours:

Here's a roundup of top developments in the biotech space over the last 24 hours:

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

CNBC

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Roche Holdings AG (OTC:RHHBY) said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease. Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function. The…

Jab saved one million lives, says Sir Pascal Soriot